Figure 6
From: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
Alternative dosing schedules for concurrent PI3K and MEK inhibition in dual inhibition-sensitive cancer cell lines. The cell lines were exposed to the inhibitors (ZSTK474 and PI-103 3.3 μM, CI-1040 1 μM, or their combinations) for the times indicated and analyzed with the MTS assay after 72 h. H3122, an ALK translocated and ALK inhibition-sensitive NSCLC line, was also exposed to the 0.1 μM ALK inhibitor TAE684 (TAE) for the times indicated. Error bars show SD. A dashed line is inserted at the level of the single inhibitor treatment inducing maximal growth inhibition to facilitate comparison with the dual inhibition treatments.